A5031934775- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Valve Diseases and Treatments
- Acute Myocardial Infarction Research
- Cerebrovascular and Carotid Artery Diseases
- Cardiac Imaging and Diagnostics
- Peripheral Artery Disease Management
- Cardiac Arrhythmias and Treatments
- Central Venous Catheters and Hemodialysis
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Aortic aneurysm repair treatments
- Mechanical Circulatory Support Devices
- Cardiac Arrest and Resuscitation
- Electrochemical Analysis and Applications
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Cardiac Structural Anomalies and Repair
- Clinical practice guidelines implementation
- Diabetes Treatment and Management
- Psychological and Temporal Perspectives Research
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiomyopathy and Myosin Studies
- Vascular Procedures and Complications
Rijnstate Hospital
2016-2025
Medisch Spectrum Twente
2008-2021
Radboud University Nijmegen
2009
Radboud University Medical Center
2009
Maastricht University
2000-2002
University of Amsterdam
1991
Stenting small-vessel lesions has an increased adverse cardiovascular event risk. Very thin-strut or ultrathin-strut drug-eluting stents might reduce this risk, but data are scarce.To assess the outcome of all-comer patients with small coronary vessel treated 3 dissimilar types stents.This is a prespecified substudy Comparison Biodegradable Polymer and Durable Drug-eluting Stents in All Comers Population (BIO-RESORT) trial, investigator-initiated, randomized, patient-blinded comparative...
The aim of this article is to present the method and results data quality control system audit within Netherlands Heart Registration (NHR) using patients treated with percutaneous coronary intervention (PCI) in as an example.The NHR a Dutch nationwide registry all cardiac interventions, comprising from 71 hospitals, which 30 are or heart centres. Each year, NHR, validation verification performed by standard controls monitoring visits (audits). For audit 2019, sample 50-100 medical records...
The study sought to evaluate for the first time 5-year outcomes after treating an all-comers population with newer-generation cobalt chromium-based Resolute Integrity zotarolimus-eluting stents (ZES) (Medtronic, Santa Rosa, California) versus platinum PROMUS Element everolimus eluting (EES) (Boston Scientific, Natick, Massachusetts). DUTCH PEERS (TWENTE II) (DUrable polymer-based sTent CHallenge of Promus ElemEnt ReSolute integrity: TWENTE trial is a randomized, multicenter, single-blinded,...
Aims:The aim of the study was to evaluate two-year clinical outcome all-comer trial participants who were treated with two very different thin-strut biodegradable polymer versus durable drug-eluting stents (DES).Prolonged after discontinuation dual antiplatelet therapy is particular interest, given highly dissimilar types, amount, distribution, and degradation speed both DES. Methods results:The BIO-RESORT (NCT01674803) randomly assigned 3,514 patients treatment SYNERGY everolimus-eluting...
Aims: It is unclear whether detection of prediabetes (pre-DM) by routine assessment glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) may help identify subjects increased event risk.We assessed the relation between glycaemia status one-year outcome after PCI.Methods results: Glycaemia was determined in 2,362 non-diabetic BIO-RESORT participants, treated at all four...
The aim of this study was to assess 2-year safety and efficacy the current-generation thin composite-wire-strut durable-polymer Resolute Onyx zotarolimus-eluting stent (ZES), compared with ultrathin-strut biodegradable-polymer Orsiro sirolimus-eluting (SES) in all-comers a pre-specified small-vessel subgroup analysis. ZES is widely used clinical practice, but no follow-up data beyond 1 year have been published. randomized BIONYX (Bioresorbable Polymer-Coated Versus Durable Stents) trial...
Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) is associated with high morbidity and mortality. Our study aimed to gain insights into patient characteristics, outcomes treatment strategies in CS patients. Patients who underwent percutaneous coronary intervention (PCI) between 2017 2021 were identified a nationwide registry. Data on medical history, laboratory values, angiographic features retrospectively assessed. A total of 2328 patients mean age 66 years whom 73%...
Abstract Background Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents is increasingly performed in elderly patients, who generally have more comorbidities and technically challenging target lesions. Nevertheless, there a paucity of reported data on the long-term safety efficacy PCI contemporary all-comers. Methods This prespecified secondary analysis large-scale randomized clinical trial (BIONYX; clinicaltrials.gov:NCT02508714 ) compared all-comers (≥ 75 years)...
Background In a previous trial, higher 5-year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus-eluting stents (SES). We assessed safety and efficacy of all-comers as well patients diabetes treated SES or Synergy everolimus-eluting (EES) versus durable Resolute Integrity zotarolimus-eluting (ZES). Methods Results The randomized BIO-RESORT (Comparison Biodegradable Polymer Durable Drug-Eluting Stents in an All Comers Population) trial enrolled 3514...
Abstract Background Mortality rates in patients with cardiogenic shock complicating acute myocardial infarction (AMICS) remain high despite advancements AMI care. Our study aimed to investigate the impact of prehospital symptom duration on prognosis AMICS and those receiving mechanical circulatory support (MCS). Methods results We conducted a retrospective cohort data registered Netherlands Heart Registration. A total 1,363 who underwent percutaneous coronary intervention between 2017 2021...
At 1 year, the international randomized BIONYX trial (ClinicalTrials.gov:NCT02508714) established non-inferiority regarding safety and efficacy of novel Resolute Onyx zotarolimus-eluting stent (RO-ZES) vs. Orsiro sirolimus-eluting (O-SES). Although RO-ZES is used in daily practice, no clinical results have been published beyond 2 years.
Background. If surgical revascularization is not feasible, high-risk PCI a viable option for patients with complex coronary artery disease. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides hemodynamic support in high risk periprocedural cardiogenic shock. Objective. This study aims to provide data about short-term outcomes of elective ECMO support. Methods. A retrospective single-center registry was performed on receiving VA-ECMO The outcome defined as the incidence major...
Diabetes is associated with adverse outcomes after percutaneous coronary intervention drug-eluting stents (DES), but for prediabetes this association has not been definitely established. Furthermore, in patients treated contemporary stents, bleeding data are lacking. We assessed 3-year ischemic and following treatment new-generation DES diabetes as compared to normoglycemia.For post-hoc analysis, we pooled patient-level of the BIO-RESORT BIONYX stent trials which both stratified at...
A considerable number of patients who undergo percutaneous coronary intervention (PCI) also have peripheral arterial disease (PAD) - a signal more advanced atherosclerosis. After bare metal and early-generation drug-eluting stent implantation, PAD showed inferior outcome. As stents medical treatment were further improved, we aimed to assess the impact on outcome PCI with contemporary new-generation stents.We analyzed 3-year pooled patient-level data from 4 large-scale randomized trials...